Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy.
Baglivo S, Bianconi F, Metro G, Gili A, Tofanetti FR, Bellezza G, Ricciuti B, Mandarano M, Teti V, Siggillino A, Reda MS, Chiari R, Pistola L, Sidoni A, Minotti V, Roila F, Ludovini V. Baglivo S, et al. Among authors: siggillino a. Genes (Basel). 2021 Jun 29;12(7):992. doi: 10.3390/genes12070992. Genes (Basel). 2021. PMID: 34209514 Free PMC article.
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
Metro G, Chiari R, Duranti S, Siggillino A, Fischer MJ, Giannarelli D, Ludovini V, Bennati C, Marcomigni L, Baldi A, Giansanti M, Minotti V, Crinò L. Metro G, et al. Among authors: siggillino a. Lung Cancer. 2012 Oct;78(1):81-6. doi: 10.1016/j.lungcan.2012.06.005. Epub 2012 Jul 4. Lung Cancer. 2012. PMID: 22770374
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
Ludovini V, Bianconi F, Siggillino A, Vannucci J, Baglivo S, Berti V, Tofanetti FR, Reda MS, Bellezza G, Mandarano M, Belladonna ML, Metro G, Chiari R, Sidoni A, Puma F, Minotti V, Roila F. Ludovini V, et al. Among authors: siggillino a. Genes (Basel). 2021 Feb 15;12(2):273. doi: 10.3390/genes12020273. Genes (Basel). 2021. PMID: 33671892 Free PMC article.
Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations.
Metro G, Baglivo S, Bellezza G, Mandarano M, Gili A, Marchetti G, Toraldo M, Molica C, Reda MS, Tofanetti FR, Siggillino A, Prosperi E, Giglietti A, Di Girolamo B, Garaffa M, Marasciulo F, Minotti V, Gunnellini M, Guida A, Sassi M, Sidoni A, Roila F, Ludovini V. Metro G, et al. Among authors: siggillino a. Genes (Basel). 2021 Apr 30;12(5):679. doi: 10.3390/genes12050679. Genes (Basel). 2021. PMID: 33946594 Free PMC article.
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis.
Ludovini V, Bianconi F, Siggillino A, Piobbico D, Vannucci J, Metro G, Chiari R, Bellezza G, Puma F, Della Fazia MA, Servillo G, Crinò L. Ludovini V, et al. Among authors: siggillino a. Oncotarget. 2016 May 24;7(21):30561-74. doi: 10.18632/oncotarget.8723. Oncotarget. 2016. PMID: 27081700 Free PMC article.
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
Ludovini V, Bianconi F, Pistola L, Pistola V, Chiari R, Colella R, Bellezza G, Tofanetti FR, Siggillino A, Baldelli E, Flacco A, Giuffrida D, Sidoni A, Crinò L. Ludovini V, et al. Among authors: siggillino a. Cancer Chemother Pharmacol. 2012 May;69(5):1289-99. doi: 10.1007/s00280-012-1829-7. Cancer Chemother Pharmacol. 2012. PMID: 22302407
Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients.
Ludovini V, Flacco A, Bianconi F, Ragusa M, Vannucci J, Bellezza G, Chiari R, Minotti V, Pistola L, Tofanetti FR, Siggillino A, Baldelli E, Sidoni A, Daddi N, Puma F, Varella-Garcia M, Crinò L. Ludovini V, et al. Among authors: siggillino a. Cancer Chemother Pharmacol. 2013 Mar;71(3):671-80. doi: 10.1007/s00280-012-2056-y. Epub 2013 Jan 12. Cancer Chemother Pharmacol. 2013. PMID: 23314677 Free PMC article.
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L. Ludovini V, et al. Among authors: siggillino a. J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b. J Thorac Oncol. 2011. PMID: 21258250 Free article.
Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
Ludovini V, Floriani I, Pistola L, Minotti V, Meacci M, Chiari R, Garavaglia D, Tofanetti FR, Flacco A, Siggillino A, Baldelli E, Tonato M, Crinò L. Ludovini V, et al. Among authors: siggillino a. J Thorac Oncol. 2011 Dec;6(12):2018-26. doi: 10.1097/JTO.0b013e3182307e1f. J Thorac Oncol. 2011. PMID: 22052224 Free article.
22 results